Data Sheet

Product Name:	FIDAS-3
Cat. No.:	CS-0119764
CAS No.:	1266684-01-8
Molecular Formula:	$C_{16}H_{15}F_2N$
Molecular Weight:	259.29
Target:	Wnt
Pathway:	Stem Cell/Wnt
Solubility:	DMSO : 100 mg/mL (385.67 mM; Need ultrasonic)



BIOLOGICAL ACTIVITY:

FIDAS-3 is a stilbene derivative and is a potent **Wnt** inhibitor with an **IC_{50}** of 4.9 μM for **methionine S-adenosyltransferase 2A (MAT2A)**. FIDAS-3 effectively competes against S-adenosylmethionine (SAM) for **MAT2A** binding. FIDAS-3 has anticancer activities [1][2]. IC50 & Target: IC50: 4.9 μM (Methionine S-adenosyltransferase 2A (MAT2A))[1] **In Vitro:** FIDAS-3 (3 μM; 7 days; LS174T cells) treatment significantly inhibits the proliferation of LS174T cells[1].

FIDAS-3 (3-10 μM) treatment inhibits the expression of c-Myc and cyclinD1 in LS174T CRC cells. And FIDAS-3 induces the expression of cell cycle inhibitor, $p21^{WAF1/CIP1}$[1].

FIDAS-3 (10 μM; 36 h) treatment reduces the levels of both S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) in LS174T cells[1]. **In Vivo:** FIDAS-3 (20 mg/kg; intraperitoneal injection; daily; for one months; C57BL/6J athymic nude mice) treatment significantly inhibits the growth of xenograft tumors[2].

References:

[1]. Zhang W, et al. Fluorinated N,N-dialkylaminostilbenes repress colon cancer by targeting methionine S-adenosyltransferase 2A. ACS Chem Biol. 2013 Apr 19;8(4):796-803.

[2]. Zhang W, et al. Fluorinated N,N-dialkylaminostilbenes for Wnt pathway inhibition and colon cancer repression. J Med Chem. 2011 Mar 10;54(5):1288-97.

CAIndexNames:

Benzenamine, 4-[(1E)-2-(2,6-difluorophenyl)ethenyl]-N,N-dimethyl-

SMILES:

CN(C)C1=CC=C(/C=C/C2=C(F)C=CC=C2F)C=C1

Tel: 610-426-3128 Fax: 888-484-5008 E-mail: sales@ChemScene.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA